PRA Health Sciences (PRAH) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Share on StockTwits

PRA Health Sciences (NASDAQ:PRAH) posted its quarterly earnings data on Wednesday. The medical research company reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.06, reports. The business had revenue of $717.60 million during the quarter, compared to analysts’ expectations of $729.63 million. PRA Health Sciences had a net margin of 4.25% and a return on equity of 24.52%. The business’s revenue was up 23.3% on a year-over-year basis. During the same period last year, the firm posted $0.88 earnings per share. PRA Health Sciences updated its FY 2018 guidance to $4.22-4.27 EPS and its FY18 guidance to $4.22-4.27 EPS.

NASDAQ:PRAH traded up $2.33 during trading hours on Thursday, reaching $99.20. 41,552 shares of the company’s stock were exchanged, compared to its average volume of 410,829. The stock has a market capitalization of $6.09 billion, a price-to-earnings ratio of 30.90, a PEG ratio of 1.39 and a beta of 0.51. PRA Health Sciences has a 12 month low of $76.39 and a 12 month high of $112.88. The company has a debt-to-equity ratio of 1.33, a quick ratio of 0.93 and a current ratio of 0.93.

Several research analysts have recently issued reports on PRAH shares. Mizuho set a $100.00 price objective on shares of PRA Health Sciences and gave the company a “hold” rating in a report on Monday, August 6th. UBS Group started coverage on shares of PRA Health Sciences in a report on Tuesday, October 9th. They issued a “neutral” rating for the company. BidaskClub upgraded shares of PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 25th. Robert W. Baird increased their price objective on shares of PRA Health Sciences from $112.00 to $116.00 and gave the company an “outperform” rating in a report on Tuesday, September 11th. Finally, Barclays increased their price objective on shares of PRA Health Sciences from $100.00 to $115.00 and gave the company an “overweight” rating in a report on Thursday, August 2nd. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $110.50.

In related news, major shareholder Pra Investors L.P. Kkr sold 6,500,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 9th. The shares were sold at an average price of $101.01, for a total transaction of $656,565,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.85% of the company’s stock.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Recommended Story: How is an ETF different from a mutual fund?

Earnings History for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with's FREE daily email newsletter.

Leave a Reply